CAJ | 학술논문

目的：：探讨培美曲赛对初治或复治晚期非小细胞肺癌( non-small cell lung cancer,NSCLC)患者的安全性和有效性。方法：经病理学或细胞学确诊的晚期NSCLC患者41例,其中一线治疗18例,二线治疗23例。培美曲赛500 mg/m2(第1天)+顺铂25 mg/m2(第2、3、4天)或卡铂AUC=5(第1天)静脉滴注,每3周为1个周期；评价安全性及有效性。结果：18例一线治疗患者中无完全缓解病例,部分缓解7例,稳定4例,进展7例,有效率38.89%,疾病控制率61.11%,中位无疾病进展时间6.8个月。23例二线治疗患者中无完全缓解病例,部分缓解2例,稳定9例,进展12例,有效率8.70%,疾病控制率47.83%,中位无进展生存时间2.6个月。2组主要不良反应为乏力、白细胞下降、贫血和胃肠道反应。结论：培美曲赛联合铂类方案一线、二线治疗晚期NSCLC疗效确切,安全性高,耐受性较好。
목적：：탐토배미곡새대초치혹복치만기비소세포폐암( non-small cell lung cancer,NSCLC)환자적안전성화유효성。방법：경병이학혹세포학학진적만기NSCLC환자41례,기중일선치료18례,이선치료23례。배미곡새500 mg/m2(제1천)+순박25 mg/m2(제2、3、4천)혹잡박AUC=5(제1천)정맥적주,매3주위1개주기；평개안전성급유효성。결과：18례일선치료환자중무완전완해병례,부분완해7례,은정4례,진전7례,유효솔38.89%,질병공제솔61.11%,중위무질병진전시간6.8개월。23례이선치료환자중무완전완해병례,부분완해2례,은정9례,진전12례,유효솔8.70%,질병공제솔47.83%,중위무진전생존시간2.6개월。2조주요불량반응위핍력、백세포하강、빈혈화위장도반응。결론：배미곡새연합박류방안일선、이선치료만기NSCLC료효학절,안전성고,내수성교호。
Objective:To investigate the safety and effectiveness of the pemetrexed in the treatment of the initial or recurrent advanced non-small cell lung cancer( NSCLC) . Methods:The 18 cases of the first-line treatment and 23 cases of the secondary-line treatment in 41 cases with advanced NSCLC identified by pathology or cytology were treated with 500 mg/m2 of pemetrexed at the first day combined with 25 mg/m2 of cisplatin at 2,3 and 4 days or 5 AUC of carboplatin at the first day by intravenous drip,3 weeks for a course. The safety and effectiveness of treatment were evaluated. Results:Partial response in 7 cases,stabilization in 4 cases,progress in 7 cases and no complete response cases in 18 cases with the first-line treatment were found,the effective rate and disease control rate were 38. 89%and 61. 11%, respectively, and the median progression-free survival time of which was 6. 8 months. Partial response in 2 cases, stabilization in 9 cases,progress in 12 cases and no complete response cases in 23 cases with the second-line treatment were found,the effective rate and disease control rate were 8. 70% and 47. 83%,respectively,and the median progression-free survival time of which was 2. 6 months. The major adverse reactions in two groups included fatigue,white blood cells decreasing,anemia and gastrointestinal tract reaction. Conclusions:The effects of pemetrexed combined with platinum in the first-line and second-line treatment of advanced NSCLC are good,high safety and good tolerance.